Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Wijetunga, Imeshi; McVeigh, Laura E.; Charalambous, Antonia; Antanaviciute, Agne; Carr, Ian; Nair, Amit; Prasad, K. Raj; Ingram, Nicola; Coletta, P. Louise

doi:10.3390/cancers12102817

Cited by 4 publications

(4 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These bioimaging applications can be combined with therapeutic applications, such as drug delivery and PTT, to simultaneously perform treatment and diagnosis to enable precision medicine that can be tailored to each patient ( Moorkoth et al, 2021 ; Yang et al, 2021 ). Nanoscale particles can be targeted to desired positions through surface functionality ( Wijetunga et al, 2020 ). In particular, the utilization of hollow gold nanostructures can enhance the efficiency of theranostics owing to their inherent characteristics.…”

Section: Biomedical Applications Of Hollow Gold Nanostructuresmentioning

confidence: 99%

Recent Advances in Hollow Gold Nanostructures for Biomedical Applications

et al. 2021

View full text Add to dashboard Cite

The localized surface plasmon resonance of metallic nanoparticles has attracted much attention owing to its unique characteristics, including the enhancement of signals in sensors and photothermal effects. In particular, hollow gold nanostructures are highly promising for practical applications, with significant advantages being found in their material properties and structures: 1) the interaction between the outer surface plasmon mode and inner cavity mode leads to a greater resonance, allowing it to absorb near-infrared light, which can readily penetrate tissue; 2) it has anti-corrosiveness and good biocompatibility, which makes it suitable for biomedical applications; 3) it shows a reduced net density and large surface area, allowing the possibility of nanocarriers for drug delivery. In this review, we present information on the classification, characteristics, and synthetic methods of hollow gold nanostructures; discuss the recent advances in hollow gold nanostructures in biomedical applications, including biosensing, bioimaging, photothermal therapy, and drug delivery; and report on the existing challenges and prospects for hollow gold nanostructures.

show abstract

Section: Biomedical Applications Of Hollow Gold Nanostructuresmentioning

confidence: 99%

Recent Advances in Hollow Gold Nanostructures for Biomedical Applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In light of this, we present our interactive dashboard, StarGazer, which aims to address these challenges by integrating three different datatypes (i.e., disease-target association, target druggability, and target protein-protein interaction) into a novel scoring system, utilizing real-time API calls and Python-based Streamlit technology. While these types of datasets have been used for numerous repositioning studies separately ( Liu et al, 2014 ; Khaladkar et al, 2017 ; Hermawan et al, 2020 ; Wijetunga et al, 2020 ; Adikusuma et al, 2021 ; Attique et al, 2021 ; Ghoussaini et al, 2021 ; Portelli et al, 2021 ; Tan et al, 2021 ; Varghese and Majumdar, 2022 ; Zhao et al, 2022 ), StarGazer represents the first ever integration of the PheWAS catalog, Open Targets, STRING and Pharos, all of which are well-curated, well-studied, open access databases. Furthermore, computational repositioning studies focus largely on singular diseases, phenotypes or drugs, but StarGazer is equipped for flexible investigation into any of the 1,844 phenotypes and traits within the dashboard.…”

Section: Introductionmentioning

confidence: 99%

StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit

et al. 2022

View full text Add to dashboard Cite

Target prioritization is essential for drug discovery and repositioning. Applying computational methods to analyze and process multi-omics data to find new drug targets is a practical approach for achieving this. Despite an increasing number of methods for generating datasets such as genomics, phenomics, and proteomics, attempts to integrate and mine such datasets remain limited in scope. Developing hybrid intelligence solutions that combine human intelligence in the scientific domain and disease biology with the ability to mine multiple databases simultaneously may help augment drug target discovery and identify novel drug-indication associations. We believe that integrating different data sources using a singular numerical scoring system in a hybrid intelligent framework could help to bridge these different omics layers and facilitate rapid drug target prioritization for studies in drug discovery, development or repositioning. Herein, we describe our prototype of the StarGazer pipeline which combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits, and is available via https://github.com/AstraZeneca/StarGazer.

show abstract

“…These biomarkers include CA19-9, CLDN18, TNC, MMP9, and EGFR. 9 Typically, CC presents with painless jaundice, abdominal pain, weight loss, and potentially changes in urine color. The patient typically has elevated LFTs, and diagnosis is confirmed with tissue biopsy with ERCP or percutaneously.…”

Section: Introductionmentioning

confidence: 99%

Hepatocellular-Cholangiocarcinoma Collision Tumors: An Update of Current Management Practices

Goodwin

Lou

Butchy

et al. 2022

The American Surgeon™

View full text Add to dashboard Cite

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary hepatic collision tumor, with an incidence ranging from 0.4 to 14.2%. Given the diagnostic challenges and lack of randomized trials, standardized treatment has yet to be established. We aim to review the literature to summarize the diagnosis, molecular characteristics, current treatment modalities, and challenges for cHCC-CC. A literature review was performed using PubMed. We included studies investigating and describing cHCC-CC, focusing on surgical, medical, and radiologic treatments. Overall prognosis is poor, with a 5-year survival rate under 30%. Minor or major hepatectomy with R0 resection is the only curative treatment; however, recurrence is likely (as high as 50% within 5 years). The role of liver transplantation is also highly debated given the biliary nature of these tumors, with cHCC-CC as a relative contraindication for liver transplantation. Although gemcitabine-based treatments had higher progression-free survival over sorafenib, there is no standard chemotherapy regimen. Treatment with gemcitabine and platinum demonstrates improved disease control rates compared to gemcitabine in conjunction with 5-fluorouracil (78.4% verse 38.5% respectively). Additionally, platinum-containing chemotherapy regimens exhibit a higher overall response rate than non-platinum regimens (21.4% verse 7.0% respectively). These molecular-directed therapies have prolonged survival for HCC, but further investigation needs to be done to assess their utility in patients with cHCC-CC. cHCC-CC is a rare and complex subset of primary hepatic neoplasms with a dismal prognosis and unstandardized treatment options. Further trials need to be performed to investigate systemic chemotherapy and immunotherapy options for patients with unresectable disease.

show abstract

Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Cited by 4 publications

References 97 publications

Recent Advances in Hollow Gold Nanostructures for Biomedical Applications

Recent Advances in Hollow Gold Nanostructures for Biomedical Applications

StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit

Hepatocellular-Cholangiocarcinoma Collision Tumors: An Update of Current Management Practices

Contact Info

Product

Resources

About